Personal opinion here, but I would say it a combination of factors:
1. Reduction in selling pressure from seller paying for options.
2. General optimism about biotech - DXB, CU6 and TLX are all doing very well.
3. Relief that the bonus option scheme was a success taking away fears of a capital raise.
4. Knowledge that the AML trial is now going to be funded.
Personal opinion here, but I would say it a combination of...
-
- There are more pages in this discussion • 1,879 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.030(1.90%) |
Mkt cap ! $267.6M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.55 | $85.03K | 54.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 325 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 900 | 1 |
View Market Depth
| Last trade - 11.33am 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |